IDH1 and central nervous system cancer: These signs of differentiation were associated with a better clinical response to ivosidenib and longer progression-free survival.64 Translational data from IDH1/2mt glioma treated with mtIDH1/2 inhibitors are not available, probably due to the inherent difficulties of obtaining multiple tumor samples over time in glioma patients.